University of Milano-Bicocca

European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

Retrieved on: 
Wednesday, September 20, 2023
Oncology, Health, Consumer, Women, Clinical Trials, Pharmaceutical, Biotechnology, University, Civil service commission, Progression-free survival, Creatinine, Anemia, Triglyceride, ESR1, Neoplasm, Safety, CDK, Cholesterol, European Medicines Agency, MBC, Indigestion, Advanced Therapy Medicinal Product, Constipation, Woman, Mutation, Multimedia, SOC, Arthralgia, Doctor of Philosophy, Diarrhea, PFS, Abdominal pain, EMA, Committee for Medicinal Products for Human Use, Vomiting, Fatigue, European Institute, Back pain, European Institute of Oncology, IRCCS, HIV disease progression rates, MD, Patient, European, Risk, Division, Drug development, Nausea, Headache, CHMP, Death, Potassium, University of Milano-Bicocca, Disease, European Commission, ER, Breast cancer, Pharmaceutical industry

With this approval, ORSERDU is the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.

Key Points: 
  • With this approval, ORSERDU is the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.
  • ESR1 mutations are acquired mutations that develop as a result of exposure to endocrine therapy, and they are found in up to 40% of patients with ER+, HER2- mBC.
  • ESR1 mutations are a known driver of resistance to standard endocrine therapy, and until now, the tumors that harbor these mutations have been more difficult to treat.
  • The primary endpoints of the study were PFS in the overall patient population and in patients with ESR1 mutations.

Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

Retrieved on: 
Friday, July 21, 2023
Medicine, Neoplasm, European Medicines Agency, Diarrhea, Arthralgia, Doctor of Philosophy, Committee, IRCCS, MD, Patient, Division, Risk, European, Committee for Medicinal Products for Human Use, AST, University of Milano-Bicocca, Fatigue, University, Cholesterol, Constipation, Bone pain, EMA, Vomiting, Back pain, HIV disease progression rates, ALT, Headache, Death, Elacestrant, Civil service commission, Creatinine, Triglyceride, CDK, MBC, Indigestion, SOC, Abdominal pain, PFS, European Institute of Oncology, Menarini, European Commission, CHMP, Thrombosis, Progression-free survival, Anemia, ESR1, Advanced Therapy Medicinal Product, Woman, Periodic breathing, European Institute, Drug development, Nausea, Potassium, ER, Breast cancer, Medical imaging, Pharmaceutical industry, EU

ORSERDU would be the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.

Key Points: 
  • ORSERDU would be the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.
  • "Patients living with metastatic breast cancer are in need of efficacious and tolerable treatment options.
  • ORSERDU, if approved, will also provide a convenient daily oral treatment," said Elcin Barker Ergun, CEO of the Menarini Group.
  • The primary endpoints of the study were PFS in the overall patient population and in patients with ESR1 mutations.

Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

Retrieved on: 
Friday, July 21, 2023
Medicine, Neoplasm, European Medicines Agency, Diarrhea, Arthralgia, Doctor of Philosophy, Committee, IRCCS, MD, Patient, Division, Risk, European, Committee for Medicinal Products for Human Use, AST, University of Milano-Bicocca, Fatigue, University, Cholesterol, Constipation, Bone pain, EMA, Vomiting, Back pain, HIV disease progression rates, ALT, Headache, Death, Elacestrant, Civil service commission, Creatinine, Triglyceride, CDK, MBC, Indigestion, SOC, Abdominal pain, PFS, European Institute of Oncology, Menarini, European Commission, CHMP, Thrombosis, Progression-free survival, Anemia, ESR1, Advanced Therapy Medicinal Product, Woman, Periodic breathing, European Institute, Drug development, Nausea, Potassium, ER, Breast cancer, Medical imaging, Pharmaceutical industry, EU

ORSERDU would be the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.

Key Points: 
  • ORSERDU would be the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.
  • "Patients living with metastatic breast cancer are in need of efficacious and tolerable treatment options.
  • ORSERDU, if approved, will also provide a convenient daily oral treatment," said Elcin Barker Ergun, CEO of the Menarini Group.
  • The primary endpoints of the study were PFS in the overall patient population and in patients with ESR1 mutations.

Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

Retrieved on: 
Friday, July 21, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Thrombosis, University, Civil service commission, Progression-free survival, Creatinine, Anemia, Triglyceride, ESR1, Neoplasm, CDK, Cholesterol, European Medicines Agency, MBC, Indigestion, Committee for Medicinal Products for Human Use, Constipation, Woman, Mutation, Periodic breathing, Multimedia, SOC, Doctor of Philosophy, Arthralgia, PFS, Diarrhea, Abdominal pain, Bone pain, Committee, EMA, Vomiting, European Institute, Back pain, European Institute of Oncology, IRCCS, HIV disease progression rates, MD, Patient, Division, Risk, European, Drug development, Nausea, ALT, Headache, CHMP, AST, Death, Potassium, University of Milano-Bicocca, European Commission, ER, Fatigue, Pharmaceutical industry, EU

ORSERDU would be the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.

Key Points: 
  • ORSERDU would be the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations.
  • “Patients living with metastatic breast cancer are in need of efficacious and tolerable treatment options.
  • ORSERDU, if approved, will also provide a convenient daily oral treatment,” said Elcin Barker Ergun, CEO of the Menarini Group.
  • The primary endpoints of the study were PFS in the overall patient population and in patients with ESR1 mutations.

CoImmune Announces Publication of Preclinical Data Demonstrating Efficacy and Specificity of CAR-CIK Cells in Acute Myeloid Leukemia

Retrieved on: 
Wednesday, July 5, 2023
HSPC, University, Pediatrics, Toxicity, Acute myeloid leukemia, CAR, AML, Science, Cytokine release syndrome, Patient, CD33, CD123, American Society of Hematology, Risk, Growth, Toxic shock syndrome toxin-1, Leukemia, Society, Endothelium, University of Milano-Bicocca, Vaccine

DURHAM, N.C., July 5, 2023 /PRNewswire/ -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the publication of preclinical data demonstrating that a strategy based on the company's proprietary Chimeric Antigen Receptor-Cytokine Induced Killer (CAR-CIK) cell platform provides advantages over single-targeting CARs including improved efficacy and high specificity in a model of acute myeloid leukemia (AML). The preclinical data are published in Blood Advances, a peer-reviewed journal of the American Society of Hematology.

Key Points: 
  • The preclinical data are published in Blood Advances, a peer-reviewed journal of the American Society of Hematology.
  • The dual strategy demonstrated powerful antitumor efficacy against AML targets without any relevant toxicity on hematopoietic stem and progenitor cells (HSPCs) and endothelial cells.
  • Specifically, the researchers found:
    CD123 and/or CD33 knockout impairs leukemia growth by modulating multiple cancer pathways in a model of NPM1-mutated AML.
  • Low affinity CAR-CIK cells preserve antileukemic efficacy in vitro and improve antitumor control in vivo.

Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer

Retrieved on: 
Tuesday, June 27, 2023
Bevacizumab, Doctor of Pharmacy, University, Obstetrics, American Journal of Clinical Oncology, Progression-free survival, Associate professor, American Society of Clinical Oncology, OS, Woman, Doctor of Philosophy, JCO, PFS, European Institute of Oncology, ASCO, Control, Journal, IRCCS, Dor, University of Milano-Bicocca, HIV disease progression rates, Risk, CORT, Death, Society, PARK, Chair, Pharmaceutical industry, MD, Gynaecology, Patient

Patients who would have met the eligibility requirements for Corcept’s confirmatory Phase 3 ROSELLA trial did especially well.

Key Points: 
  • Patients who would have met the eligibility requirements for Corcept’s confirmatory Phase 3 ROSELLA trial did especially well.
  • “The benefits experienced by patients in the intermittent dosing group are meaningful especially given the simple, oral dosing and favorable safety profile of relacorilant.
  • Our single goal is to replicate the great results seen in our phase 2 trial,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.
  • “We believe relacorilant has the potential to become a new standard of care for all patients with platinum-resistant ovarian cancer.”

Mediso installs 100% cryogen-free 7T MRI at the University of Milano-Bicocca, Italy

Retrieved on: 
Thursday, June 1, 2023
Maintenance, DTI, University, University of Milano-Bicocca, Mediso, Bureau of Medicine and Surgery, MRI, SNR, Growth, Medical imaging, Mortar (masonry), Medicine

BUDAPEST, Hungary, June 1, 2023 /PRNewswire/ -- Mediso Medical Imaging Systems recently installed a state-of-the-art 7T MRI at the University of Milano-Bicocca.

Key Points: 
  • BUDAPEST, Hungary, June 1, 2023 /PRNewswire/ -- Mediso Medical Imaging Systems recently installed a state-of-the-art 7T MRI at the University of Milano-Bicocca.
  • The nanoScan® MRI 7T installed is equipped with a state-of-the-art cryogen-free superconducting magnet.
  • Uniquely on the preclinical market, the pulse tube cryocooler is mounted at the back of the scanner to minimize vibrations thus delivering ghost-free images.
  • "The preclinical research groups of the Department of Medicine and Surgery of University of Milano-Bicocca are very pleased to include in the imaging facilities the nanoScan® 7T preclinical MRI scanner.

Mediso installs 100% cryogen-free 7T MRI at the University of Milano-Bicocca, Italy

Retrieved on: 
Thursday, June 1, 2023
Maintenance, DTI, University, University of Milano-Bicocca, Mediso, Bureau of Medicine and Surgery, MRI, SNR, Growth, Medical imaging, Mortar (masonry), Medicine

BUDAPEST, Hungary, June 1, 2023 /PRNewswire/ -- Mediso Medical Imaging Systems recently installed a state-of-the-art 7T MRI at the University of Milano-Bicocca.

Key Points: 
  • BUDAPEST, Hungary, June 1, 2023 /PRNewswire/ -- Mediso Medical Imaging Systems recently installed a state-of-the-art 7T MRI at the University of Milano-Bicocca.
  • The nanoScan® MRI 7T installed is equipped with a state-of-the-art cryogen-free superconducting magnet.
  • Uniquely on the preclinical market, the pulse tube cryocooler is mounted at the back of the scanner to minimize vibrations thus delivering ghost-free images.
  • "The preclinical research groups of the Department of Medicine and Surgery of University of Milano-Bicocca are very pleased to include in the imaging facilities the nanoScan® 7T preclinical MRI scanner.

EQS-News: TVM Capital Life Science Announces Promotions to Recognize Significant Contributions of Up-and-Coming Leaders

Retrieved on: 
Thursday, February 23, 2023
Molecular biology, Doctor of Philosophy, University, Zurich Insurance Group, TVM, POLIMI Graduate School of Management, MBA, Partnership, IND, Alan Catello Grazioso, Investment, ETH Zurich, Federal Institute of Science and Technology, Economics, ITN, Therapy, Master of Science, Swiss, Investment banking, University of Milano-Bicocca, Pharmaceutical industry, Management

We are delighted to recognize the contributions Valentina, Catello and Philipp have made to the Company as well as their achievements with these well-deserved promotions.

Key Points: 
  • We are delighted to recognize the contributions Valentina, Catello and Philipp have made to the Company as well as their achievements with these well-deserved promotions.
  • It is gratifying to see each of them expand their roles in our team and take on increased responsibilities,“ said Dr. Luc Marengère, Managing Partner at TVM Capital Life Science.
  • Dr. Hubert Birner, Managing Partner at TVM Capital Life Science, added: “These promotions underscore TVM’s commitment to professional development and talent recognition.
  • Growing the next generation of leaders is an integral part of our strategy to position TVM for continued success.

TVM Capital Life Science Announces Promotions to Recognize Significant Contributions of Up-and-Coming Leaders

Retrieved on: 
Thursday, February 23, 2023
Molecular biology, Doctor of Philosophy, University, Zurich Insurance Group, TVM, POLIMI Graduate School of Management, MBA, Partnership, IND, Alan Catello Grazioso, Investment, ETH Zurich, Federal Institute of Science and Technology, Economics, ITN, Therapy, Master of Science, Swiss, Investment banking, University of Milano-Bicocca, Management, Pharmaceutical industry

We are delighted to recognize the contributions Valentina, Catello and Philipp have made to the Company as well as their achievements with these well-deserved promotions.

Key Points: 
  • We are delighted to recognize the contributions Valentina, Catello and Philipp have made to the Company as well as their achievements with these well-deserved promotions.
  • It is gratifying to see each of them expand their roles in our team and take on increased responsibilities,” said Dr. Luc Marengère, Managing Partner at TVM Capital Life Science.
  • Dr. Hubert Birner, Managing Partner at TVM Capital Life Science, added: “These promotions underscore TVM’s commitment to professional development and talent recognition.
  • Growing the next generation of leaders is an integral part of our strategy to position TVM for continued success.